JP2021518443A5 - - Google Patents

Info

Publication number
JP2021518443A5
JP2021518443A5 JP2021500778A JP2021500778A JP2021518443A5 JP 2021518443 A5 JP2021518443 A5 JP 2021518443A5 JP 2021500778 A JP2021500778 A JP 2021500778A JP 2021500778 A JP2021500778 A JP 2021500778A JP 2021518443 A5 JP2021518443 A5 JP 2021518443A5
Authority
JP
Japan
Prior art keywords
composition according
concentration
phosphatidylserine lipid
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500778A
Other languages
English (en)
Japanese (ja)
Other versions
JP7081865B2 (ja
JP2021518443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/059016 external-priority patent/WO2019182650A1/en
Publication of JP2021518443A publication Critical patent/JP2021518443A/ja
Publication of JP2021518443A5 publication Critical patent/JP2021518443A5/ja
Priority to JP2022082176A priority Critical patent/JP7313091B2/ja
Application granted granted Critical
Publication of JP7081865B2 publication Critical patent/JP7081865B2/ja
Priority to JP2023109939A priority patent/JP2023118847A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500778A 2018-03-23 2018-11-02 サポシンc薬学的組成物および癌を治療する方法 Active JP7081865B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022082176A JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンc薬学的組成物および癌を治療する方法
JP2023109939A JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンc薬学的組成物および癌を治療する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647058P 2018-03-23 2018-03-23
US62/647,058 2018-03-23
US201862678668P 2018-05-31 2018-05-31
US62/678,668 2018-05-31
PCT/US2018/059016 WO2019182650A1 (en) 2018-03-23 2018-11-02 Saposin c pharmaceutical compositions and methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082176A Division JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンc薬学的組成物および癌を治療する方法

Publications (3)

Publication Number Publication Date
JP2021518443A JP2021518443A (ja) 2021-08-02
JP2021518443A5 true JP2021518443A5 (cg-RX-API-DMAC7.html) 2022-03-14
JP7081865B2 JP7081865B2 (ja) 2022-06-07

Family

ID=64664378

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021500778A Active JP7081865B2 (ja) 2018-03-23 2018-11-02 サポシンc薬学的組成物および癌を治療する方法
JP2022082176A Active JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンc薬学的組成物および癌を治療する方法
JP2023109939A Pending JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンc薬学的組成物および癌を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022082176A Active JP7313091B2 (ja) 2018-03-23 2022-05-19 サポシンc薬学的組成物および癌を治療する方法
JP2023109939A Pending JP2023118847A (ja) 2018-03-23 2023-07-04 サポシンc薬学的組成物および癌を治療する方法

Country Status (16)

Country Link
US (3) US10682411B2 (cg-RX-API-DMAC7.html)
EP (2) EP4005562A1 (cg-RX-API-DMAC7.html)
JP (3) JP7081865B2 (cg-RX-API-DMAC7.html)
KR (2) KR102483046B1 (cg-RX-API-DMAC7.html)
CN (2) CN111902133B (cg-RX-API-DMAC7.html)
AU (1) AU2018414543B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018334A2 (cg-RX-API-DMAC7.html)
CA (1) CA3094928A1 (cg-RX-API-DMAC7.html)
ES (1) ES2895180T3 (cg-RX-API-DMAC7.html)
IL (1) IL277313B (cg-RX-API-DMAC7.html)
MX (1) MX2020009829A (cg-RX-API-DMAC7.html)
PL (1) PL3768246T3 (cg-RX-API-DMAC7.html)
PT (1) PT3768246T (cg-RX-API-DMAC7.html)
RU (1) RU2767199C1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007884UA (cg-RX-API-DMAC7.html)
WO (1) WO2019182650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009829A (es) * 2018-03-23 2021-01-08 Bexion Pharmaceuticals Inc Composiciones farmaceuticas de saposina c y metodos para tratar el cancer.
CA3176637A1 (en) 2021-01-09 2022-07-14 Bexion Pharmaceuticals Inc. Methods of reducing neuropathy and neuropathic symptoms and treating cancer
US20260069705A1 (en) * 2022-06-09 2026-03-12 The Children's Medical Center Corporation Methods and compositions for enhanced antigen presentation in the tumor microenvironment

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
US6872406B2 (en) 2000-02-11 2005-03-29 Children's Hospital Research Foundation Fusogenic properties of saposin C and related proteins and polypeptides for application to transmembrane drug delivery systems
CN100366286C (zh) 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN101583346B (zh) 2006-04-28 2015-08-19 儿童医院医疗中心 用于穿膜药物递送系统的皂化蛋白c和相关蛋白及肽的促融合性质
RU2008148329A (ru) 2006-05-09 2010-06-20 Колгейт-Палмолив Компани (US) Система ухода за ротовой полостью
CA2666953A1 (en) 2006-10-20 2008-05-02 Children's Hospital Medical Center Spontaneous forming ellipsoidal phospholipid unilamellar vesicles
CN101209251A (zh) 2006-12-28 2008-07-02 中国科学院理化技术研究所 含有紫杉醇或多烯紫杉醇的弹性纳米囊泡制剂及其制备方法
WO2009049422A1 (en) * 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
AU2008363813A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
US7794969B1 (en) 2009-07-09 2010-09-14 Joule Unlimited, Inc. Methods and compositions for the recombinant biosynthesis of n-alkanes
CN102614125B (zh) 2011-02-01 2018-11-02 常州长吉生物技术开发有限公司 SapC-磷脂纳米囊泡冻干制剂、其制备方法及用途
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
US10760112B2 (en) * 2014-12-18 2020-09-01 Shire Human Genetic Therapies, Inc. Enzymatic activity assays for glucocerebrosidase
WO2017004408A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
CN110248673A (zh) 2016-11-21 2019-09-17 百祥制药公司 用于治疗胰腺癌的包括SapC-DOPS的联合疗法
MX2020009829A (es) * 2018-03-23 2021-01-08 Bexion Pharmaceuticals Inc Composiciones farmaceuticas de saposina c y metodos para tratar el cancer.

Similar Documents

Publication Publication Date Title
US3993754A (en) Liposome-encapsulated actinomycin for cancer chemotherapy
TWI764943B (zh) 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
Shelly et al. Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes.
US7354579B2 (en) Method of treating cancer with a VEGF antagonist and an anti-proliferative agent
WO2019200382A1 (en) Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
CA3009918C (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
ES2328822T3 (es) Oligo-beta-(1,3)-glucano y anticuerpos monoclonales contra el cancer.
JP2003501379A (ja) ガン治療のための薬剤を充填したナノパーティクルの使用
CN112137958A (zh) 一种含阿霉素与免疫佐剂组合药物脂质体及其制备方法
CN106540256A (zh) 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
KR102929813B1 (ko) 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
George Zhu et al. The effect of vincristine–polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity
JPH07101875A (ja) 膀胱ガンに対して高い抗腫瘍活性を有するカサガイヘモシアニン
US11096893B2 (en) Glucose sensitive compositions for drug delivery
US7439234B2 (en) Method for treating cancer patients undergoing chemotherapy
WO2019023873A1 (zh) 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
US8293274B2 (en) Intestinal absorptive anti-tumor agent
JP2004504346A (ja) 骨転移の治療におけるリン酸エストラムスチンの使用
TW202023568A (zh) 用於治療癌症之組合療法
Velebny et al. Toxocara canis in mice: effect of stabilised liposomes on the larvicidal efficacy of fenbendazole and albendazole
EA004647B1 (ru) Способы потенциации внутривенного эстрамустинфосфата
CN105412917B (zh) 治疗实体瘤的抗癌组合物及其用途
JPS63170324A (ja) 血管透過性亢進剤
Castiglione et al. Liposomal doxorubicin successful treatment in an elderly non-small cell lung cancer patient: A case report